Imukin (Recombinant Human Interferon Gamma 1b)

The molecule binds to interferon gamma receptors on immune cells, activating the JAK‑STAT signaling cascade. This activation enhances macrophage microbicidal activity, increases antigen presentation, and drives a Th1‑type immune response, which together improve the body’s ability to combat intracellular pathogens and influence bone turnover.

The specific dose and dosing schedule of Imukin are determined by the prescribing clinician based on the patient’s age, weight, disease severity, and response to therapy. Healthcare providers tailor the regimen to achieve optimal clinical benefit while monitoring safety.

Safety data for recombinant human interferon gamma-1b in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To request Imukin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including cold‑chain logistics if needed—and necessary import documentation.

Imukin (interferon gamma‑1b) differs from interferon‑alpha or beta products by specifically promoting Th1 immune responses and macrophage activation, making it suitable for conditions like CGD and SMO. Other interferons target viral replication or multiple sclerosis pathways, so the choice depends on the disease mechanism and therapeutic goals.

Imukin should be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. If the product must be transported, maintain the cold chain to preserve stability and potency.

Imukin is given by subcutaneous injection, typically into the abdomen or thigh. The injection site should be rotated to minimize local reactions, and aseptic technique must be followed. Administration is performed by a healthcare professional or a trained caregiver under medical supervision.

Serious risks include severe allergic reactions such as anaphylaxis, autoimmune hepatitis, and significant hematologic abnormalities like neutropenia or thrombocytopenia. Patients should be monitored regularly for signs of these events, and treatment should be discontinued if any serious reaction occurs.

Imukin is contraindicated in individuals with known hypersensitivity to interferon gamma‑1b or any excipients in the formulation. It should also be avoided in patients receiving live attenuated vaccines or those with uncontrolled autoimmune disease unless the benefits outweigh the risks.